From Public To Private, Crossover Investors Are Back In Biotech
This article was originally published in Start Up
Traditional life-science venture is shrinking, leaving gaps for others to fill. Crossover investors are now more creative and aggressive in reaching out to the best private companies. They often seek out entrepreneurs with glittering track records of repeat success, and some crossover investors also join mezzanine rounds to familiarize themselves with an interesting new company, management team, or technology earlier and at a lower cost than on the public markets.
You may also be interested in...
Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.